0001193125-21-325959.txt : 20211110 0001193125-21-325959.hdr.sgml : 20211110 20211110160605 ACCESSION NUMBER: 0001193125-21-325959 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211110 DATE AS OF CHANGE: 20211110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revolution Medicines, Inc. CENTRAL INDEX KEY: 0001628171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472029180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39219 FILM NUMBER: 211396531 BUSINESS ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 415-766-3638 MAIL ADDRESS: STREET 1: 700 SAGINAW DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 8-K 1 d244257d8k.htm 8-K 8-K
false 0001628171 0001628171 2021-11-10 2021-11-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2021

 

 

Revolution Medicines, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39219   47-2029180

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

700 Saginaw Drive

Redwood City, California 94063

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 481-6801

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   RVMD  

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 2.02

Results of Operations and Financial Condition.

On November 10, 2021, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.
   Description
99.1    Press Release, dated November 10, 2021.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    REVOLUTION MEDICINES, INC.
Date: November 10, 2021     By:  

/s/ Mark A. Goldsmith

      Mark A. Goldsmith, M.D., Ph.D.
      President and Chief Executive Officer
EX-99.1 2 d244257dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation

Company Poised to Select Additional RAS(ON) Development Candidate in 2021; Mutant-Selective Inhibitors of KRASG13C and KRASG12D Showing Preclinical Promise

Global Phase 2 Study, RMC-4630-03, Recruiting Patients to Evaluate RMC-4630 in Combination with Lumakras

REDWOOD CITY, CA – November 10, 2021 – Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

“During the third quarter, the company’s unique capabilities and continuing momentum with our innovative RAS(ON) Inhibitors and RAS Companion Inhibitors strengthened Revolution Medicines’ leadership position in the quest to successfully treat RAS-addicted cancers. In our RAS(ON) Inhibitor portfolio, development candidates targeting KRASG12C (RMC-6291) and RASMULTI (RMC-6236) have shown compelling features and continue to advance toward the clinic. Exciting mutant-selective inhibitors of KRASG13C and KRASG12D have also emerged from our RAS(ON) drug discovery platform, and we expect to select another development candidate by year end,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines.

“We have expanded the evaluation of our SHP2 inhibitor, RMC-4630, in combination regimens with direct inhibitors of RAS. In particular, the company recently began recruiting patients in our RMC-4630-03 study under our global partnership with Sanofi and in collaboration with Amgen. This study is intended to further evaluate RMC-4630 and Lumakras in the treatment of lung cancer as a complement to the ongoing CodeBreaK 101c study of these compounds. In addition, we are gratified that Sanofi plans to sponsor a study of RMC-4630 in combination with Mirati’s KRASG12C inhibitor, adagrasib, also under our partnership.”

RAS(ON) Inhibitors – Revolution Medicines continues to build on its innovative RAS(ON) Inhibitor platform, producing an expansive collection of tri-complex inhibitors targeting diverse oncogenic RAS variants through highly differentiated chemical and pharmacologic profiles.


   

RMC-6291 (KRASG12C)—RMC-6291 is a first-in-class, potent, oral and selective tri-complex inhibitor of KRASG12C(ON) with a differentiated preclinical profile designed to address persistent unmet needs for patients with cancers driven by KRASG12C.

 

   

The company recently reported data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrating superior outcomes with orally administered RMC-6291 as compared to adagrasib in preclinical models of KRASG12C non-small cell lung cancer (NSCLC). In a head-to-head mouse clinical trial of 19 xenograft models, RMC-6291 demonstrated robust anti-tumor activity characterized by a 68% objective response rate, as compared to 42% for adagrasib in the same models. The company believes these findings support the potential for RMC-6291 as a best-in-class KRASG12C inhibitor.

 

   

The company remains on track to submit an Investigational New Drug application (IND) for RMC-6291 in the first half of 2022.

 

   

RMC-6236 (RASMULTI)—RMC-6236 is a first-in-class, potent, oral RAS-selective tri-complex, RASMULTI(ON) inhibitor designed to treat cancers driven by a variety of KRAS mutations, including those that have emerged in patients following treatment with KRASG12C(OFF) inhibitors.

 

   

The company reported data at the AACR-NCI-EORTC Conference demonstrating RMC-6236’s ability to induce significant regressions of NSCLC, pancreatic cancer and colorectal cancer (CRC) xenograft models driven by KRASG12V, KRASG12D, KRASG12C or KRASG12R. These findings add to the growing body of evidence that the company believes supports the potential of RMC-6236 as a first targeted therapy for treating many cancers for which no targeted treatment is currently available.

 

   

The company presented an expanded dataset at the Gastrointestinal Cancer Drug Development Summit demonstrating the ability of both RMC-6236 and RMC-6291 to drive tumor regressions in xenograft models of RAS-mutant CRC. The company believes these findings provide additional support for the potential of RAS(ON) inhibitors to deliver clinical benefit to patients with CRC.

 

   

Also during the AACR-NCI-EORTC Conference, the company presented preclinical data from a combination study evaluating RMC-6236 with a PD-1 inhibitor. Results from this study demonstrated that RMC-6236 alone induces anti-tumor immunity in vivo, and also exhibits additive anti-tumor benefit with checkpoint inhibition as indicated by complete and durable responses.

 

   

The company remains on track to submit an IND for RMC-6236 in the first half of 2022.

 

   

Continued expansion of other RAS(ON) Inhibitor programs – Revolution Medicines continues to progress its growing portfolio of orally bioavailable, mutant-selective RAS(ON) Inhibitors designed to target RAS variants driving RAS-addicted cancers that are unserved by targeted drugs.

 

   

The company reported data at the AACR-NCI-EORTC Conference showing the capacity of compounds from both its KRASG13C and KRASG12D programs to covalently and selectively modify their respective targets, the first compounds described with these properties. Covalent modification of KRASG12D was also demonstrated in vivo in a tumor xenograft model of KRASG12D-driven pancreatic cancer, with tumor regressions achieved following repeat oral dosing.

 

   

The company remains on track to nominate a third development candidate from its RAS(ON) inhibitor portfolio in 2021.


RAS Companion Inhibitors – Revolution Medicines continues to advance and expand multiple clinical studies of its RAS Companion Inhibitors designed to provide maximum clinical benefit in RAS-addicted cancers.

 

   

RMC-4630 (SHP2 Inhibitor) – RMC-4630, a potent, oral, selective inhibitor of the SHP2 protein, is being advanced in partnership with, and is primarily funded by, Sanofi.

 

   

RMC-4630 and KRASG12C inhibitor Lumakras (sotorasib)

 

   

Amgen’s CodeBreaK 101c study continues evaluating RMC-4630 in combination with sotorasib across multiple cancer types. To date this combination has demonstrated acceptable tolerability.

 

   

The company is actively recruiting patients for its global Phase 2 clinical trial evaluating the combination of RMC-4630 and sotorasib in patients with advanced NSCLC bearing the KRASG12C mutation. Revolution Medicines is sponsoring the RMC-4630-03 study under its global partnership with Sanofi and conducting the trial in collaboration with Amgen. The RMC-4630-03 study evaluating the combination in NSCLC patients is a complement to Amgen’s ongoing CodeBreaK 101c study exploring this combination across multiple cancer types. The company expects to have preliminary findings from the RMC-4603-03 study in the second half of 2022.

 

   

RMC-4630 and KRASG12C inhibitor adagrasib

 

  Sanofi,

the company’s global SHP2 development and commercialization partner, plans to sponsor a combination study under its global SHP2 partnership with the company evaluating RMC-4630 (also known as SAR442720) in combination with Mirati’s KRASG12C inhibitor, adagrasib. This study expands the evaluation of the potential benefit of adding RMC-4630 in this class of RAS inhibitors.

 

   

RMC-4630 and PD-1 inhibitor pembrolizumab (Keytruda®)

 

   

The TCD16210 study sponsored by Sanofi continues evaluating RMC-4630 in combination with pembrolizumab, a PD-1 inhibitor. Sanofi is planning an expansion cohort with this combination in front-line PD-L1+ NSCLC.

 

   

RMC-5552 (mTORC1/4EBP1 Inhibitor) – RMC-5552 is a potent, selective bi-steric inhibitor of mTORC1 that suppresses phosphorylation and inactivation of 4EBP1.

 

   

Enrollment and dosing are underway in a Phase 1 monotherapy dose-escalation study. The company continues to expect initial safety, pharmacokinetic and single agent activity data in 2022.

 

   

The company intends to evaluate RMC-5552 in combination with RAS inhibitors for the treatment of tumors driven by co-occurring RAS mutations and genomic activation of the mTORC1 pathway.

 

   

RMC-5845 (SOS1 Inhibitor) RMC-5845 is a potent, selective, oral inhibitor of SOS1, a major switch in the cycling of RAS(OFF) to RAS(ON).

 

   

The company expects RMC-5845 to be IND-ready by the end of 2021.


Third Quarter 2021 Financial Highlights

Cash Position: Cash, cash equivalents and marketable securities were $608.7 million as of September 30, 2021, compared to $440.7 million as of December 31, 2020. The increase was primarily due to proceeds from the company’s public equity offering in February 2021.

Revenue: Total revenue consists of revenue from the company’s collaboration agreement with Sanofi. During the third quarter of 2021, the company recorded a non-cash, non-recurring GAAP accounting adjustment that reduced collaboration revenue by $8.5 million. This non-cash revenue adjustment relates to the addition of the RMC-4630-03 study to the RMC-4630 development plan, and deprioritization of the RMC-4630-02 study. As a result of these development plan events, the company revised its estimate of the accounting transaction price and percentage of completion of work performed to date under its agreement with Sanofi, which resulted in a cumulative catch-up adjustment to collaboration revenue in this quarter. Total revenue, including the non-cash revenue adjustment, was $1.1 million for the quarter ended September 30, 2021, compared to $12.7 million for the quarter ended September 30, 2020. The decrease was primarily due to the non-cash revenue adjustment and lower reimbursed manufacturing costs.

R&D Expenses: Research and development expenses were $46.5 million for the quarter ended September 30, 2021, compared to $34.9 million for the quarter ended September 30, 2020. The increase was primarily due to an increase in research expenses associated with the company’s pre-clinical research portfolio, an increase in personnel-related expenses related to additional headcount, and an increase in stock-based compensation.

G&A Expenses: General and administrative expenses were $7.8 million for the quarter ended September 30, 2021, compared to $5.3 million for the quarter ended September 30, 2020. The increase was primarily due to an increase in stock-based compensation, an increase in personnel-related expenses related to additional headcount, and higher legal and accounting fees.

Net Loss: Net loss was $52.9 million for the quarter ended September 30, 2021, compared to a net loss of $27.2 million for the quarter ended September 30, 2020.

2021 Financial Guidance

Revolution Medicines continues to expect full year 2021 GAAP net loss to be between $170 million and $190 million, which includes estimated non-cash stock-based compensation expense of approximately $20 million.

Conference Call

Revolution Medicines will host a conference call and webcast this afternoon, November 10, 2021, at 4:30 PM Eastern (1:30 PM Pacific).

To listen to the conference call, please dial (833) 423-0425 or (918) 922-3069, provide conference ID: 9757524 and request the Revolution Medicines conference call. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the Company’s website for at least 14 days.


About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Lumakras (sotorasib) is a trademark of Amgen, Inc.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the company’s development plans and timelines and its ability to advance its portfolio and R&D pipeline; dosing and enrollment in the company’s clinical trials and the tolerability and potential efficacy of the company’s candidates being studied; the ability of the company’s therapies to inhibit frontier targets in RAS-addicted cancers; the company’s plans to advance the IND-enabling development of RMC-6291, RMC-6236 and RMC-5845; the company’s plans to study RMC-5552 in combination with RAS inhibitors; the expected timing of results from the company’s Phase 1 study of RMC-5552; the potential advantages and effectiveness of the company’s preclinical candidates, including its RAS(ON) Inhibitors; the company’s plans to nominate a third development candidate from its RAS(ON) inhibitor portfolio; the selection of a combination dose for the CodeBreak 101c study; and enrollment in and findings from the company’s RMC-4630-03 study. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ early stage of development, the process of designing and


conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on the company’s business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Contacts:

For Investors:

Vida Strategic Partners

Stephanie Diaz

415-675-7401

sdiaz@vidasp.com

For Media:

Vida Strategic Partners

Tim Brons

415-675-7402

tbrons@vidasp.com


REVOLUTION MEDICINES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

 

     Three Months Ended September 30,     Nine Months Ended September 30,  
     2021     2020     2021     2020  

Revenue:

        

Collaboration revenue

   $ 1,101     $ 12,661     $ 19,930     $ 34,232  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total revenue

     1,101       12,661       19,930       34,232  

Operating expenses:

        

Research and development

     46,473       34,871       133,267       95,246  

General and administrative

     7,791       5,341       21,758       15,603  
  

 

 

   

 

 

   

 

 

   

 

 

 

Total operating expenses

     54,264       40,212       155,025       110,849  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss from operations

     (53,163     (27,551     (135,095     (76,617

Other income (expense), net:

        

Interest income

     223       347       692       1,986  

Interest expense

     —         (17     (12     (57
  

 

 

   

 

 

   

 

 

   

 

 

 

Total other income, net

     223       330       680       1,929  
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss before income taxes

     (52,940     (27,221     (134,415     (74,688
  

 

 

   

 

 

   

 

 

   

 

 

 

Benefit from income taxes

     —         —         —         733  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss

   $ (52,940   $ (27,221   $ (134,415   $ (73,955
  

 

 

   

 

 

   

 

 

   

 

 

 

Redeemable convertible preferred stock dividends—undeclared and cumulative

     —         —         —         (2,219
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (52,940   $ (27,221   $ (134,415   $ (76,174
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss per share attributable to common stockholders—basic and diluted

   $ (0.72   $ (0.42   $ (1.85   $ (1.49
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted-average common shares used to compute net loss per share, basic and diluted

     73,535,686       64,892,868       72,467,677       51,031,003  
  

 

 

   

 

 

   

 

 

   

 

 

 


REVOLUTION MEDICINES, INC.

SELECTED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, unaudited)

 

     September 30,      December 31,  
     2021      2020  

Cash, cash equivalents and marketable securities

   $ 608,655      $ 440,741  

Working capital (1)

     571,645        406,946  

Total assets

     734,976        567,401  

Deferred revenue

     22,343        20,592  

Total liabilities

     96,772        92,725  

Total stockholders’ equity

     638,204        474,676  

 

(1)

Working capital is defined as current assets less current liabilities.

EX-101.SCH 3 rvmd-20211110.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 rvmd-20211110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 rvmd-20211110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g244257g1109130729797.jpg GRAPHIC begin 644 g244257g1109130729797.jpg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end XML 7 d244257d8k_htm.xml IDEA: XBRL DOCUMENT 0001628171 2021-11-10 2021-11-10 false 0001628171 8-K 2021-11-10 Revolution Medicines, Inc. DE 001-39219 47-2029180 700 Saginaw Drive Redwood City CA 94063 (650) 481-6801 false false false false Common Stock, $0.0001 par value per share RVMD NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 10, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001628171
Document Type 8-K
Document Period End Date Nov. 10, 2021
Entity Registrant Name Revolution Medicines, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39219
Entity Tax Identification Number 47-2029180
Entity Address, Address Line One 700 Saginaw Drive
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94063
City Area Code (650)
Local Phone Number 481-6801
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol RVMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d244257d8k.htm d244257dex991.htm rvmd-20211110.xsd rvmd-20211110_lab.xml rvmd-20211110_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d244257d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d244257d8k.htm" ] }, "labelLink": { "local": [ "rvmd-20211110_lab.xml" ] }, "presentationLink": { "local": [ "rvmd-20211110_pre.xml" ] }, "schema": { "local": [ "rvmd-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rvmd", "nsuri": "http://www.revolutionmedicines.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d244257d8k.htm", "contextRef": "duration_2021-11-10_to_2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d244257d8k.htm", "contextRef": "duration_2021-11-10_to_2021-11-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.revolutionmedicines.com//20211110/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 15 0001193125-21-325959-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-325959-xbrl.zip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end